
'Inverse' vaccines may hold key to challenge autoimmune diseases
1 of 3 | Reverse or inverse vaccines work differently from conventional immunizations like the flu shot and currently available immunosuppressant treatments for autoimmune conditions. Photo by RF._.studio/ Pexels
NEW YORK, June 30 (UPI) -- For the millions of Americans battling autoimmune disorders, new hope may be on the horizon in the form of reverse or inverse vaccines -- injections that target a specific part of the immune system. experts told UPI.
However, these injections work differently from conventional immunizations like the flu shot and currently available immunosuppressant treatments for autoimmune conditions.
They work by targeting only the specific part of the immune system that's behind diseases such as lupus, multiple sclerosis, psoriasis, rheumatoid arthritis and Type 1 diabetes, the experts say.
"Inverse vaccines are being developed to treat undesired immune responses, [and] for these situations, the body is reacting to something that is not dangerous," said Lonnie Shea, a researcher in biomedical engineering at the University of Michigan who has studied inverse vaccines and worked on some of the key technology behind them.
"A vaccine activates an immune response to a specific antigen," Shea told UPI via email. Inverse vaccines are being developed to treat undesired immune responses, [and] for these situations, the body is reacting to something that is not dangerous.
Essentially, an inverse vaccine "aims to decrease the response to a specific antigen, like insulin in Type 1 diabetes," he added.
First line of defense
When healthy, the immune system is the body's first line of defense against diseases such as cancer and infections caused by viruses and bacteria, according to the National Institutes of Health.
However, if the immune system isn't working properly, it can erroneously attack healthy cells, tissues and organs, causing autoimmune diseases that can affect any part of the body, weakening function and potentially leading to death, the NIH says.
More than 80 autoimmune diseases are known, some of which are caused by exposure to environmental toxins and have no discovered cure. At least 15 million people in the United States, or about 5% of the population, have an autoimmune disease, the agency reports.
Although no cure exists for these conditions, symptoms can be managed with drugs called immunosuppressants, which as the name suggests "broadly reduces your immune system response," Shea said.
These drugs, which are typically administered via monthly injections, can have significant side effects, including making those taking them more susceptible to infections, according to the NIH.
Many people taking them also have to be careful taking traditional vaccines, such as flu shot or COVID-19 shots because of their impact on the immune system.
Training the immune system
Developed by researchers at the University of Chicago and elsewhere, inverse vaccines use synthetic nanoparticles attached to specific disease-related proteins, or antigens, to train certain parts of the immune system to behave differently, limiting the attacks that cause autoimmune diseases, neurologist Dr. Lawrence Steinman said.
With the inverse vaccines currently being studied, the nanoparticles are designed to mimic human cell death, which is a normal process in the human body, according to the 2021 study that first documented their effectiveness in people with celiac disease, another autoimmune disorder.
Dying cells are considered foreign bodies, but the human immune system knows not to attack them.
As a result, with the nanoparticles in inverse vaccines, the immune system can be trained not to attack them, or the proteins attached to them, which effectively short-circuits the process behind autoimmune diseases, Steinman said.
"Instead of immunizing the recipient to a viral infection, the inverse vaccine tolerizes the immune system, so it will not attack our own tissues," Steinman, who has written about inverse vaccines, told UPI in an email.
Several companies are running clinical trials of inverse vaccines, including Cour Pharma, which recently completed successful phase 2 clinical trials for their use in celiac disease and another autoimmune disease, primary biliary cholangitis, according to Shea at the University of Michigan, one of the researchers who started the company.
Additional trials -- phase 2 studies are the second stage in the drug research and development process -- are starting for myasthenia gravis and Type 1 diabetes, he added.
Although more research is needed before the shots become available, a process that could take five years or more, inverse vaccines offer key advantages, Shea said.
For example, unlike immunosuppressants with their monthly dosing, the effects of inverse vaccines appear to last longer, perhaps for as much as a year, similar to conventional vaccines, research suggests.
They may also work for people with severe, life-threatening allergies, such as peanut allergies, according to Shea, who has published a study in this area using mice.
However, there's also the "risk that instead of tolerizing the human immune system to the target, the process induces conventional immunization, which would make autoimmune conditions like Type 1 diabetes and multiple sclerosis worse," Steinman said.
However, "We have come close to success in some early-stage trials," he said "Thus far, none of the results are sufficiently robust for submission in the FDA approval process."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
22 minutes ago
- Bloomberg
RFK Jr.'s Vaccine Panel Is Turning Misinformation Into Policy
Save Health and Human Services Secretary Robert F. Kennedy's dismantling of Americans' trust in — and ultimately, access to — vaccines isn't happening with one sweeping policy that grabs the public's attention. It's unfolding quickly and quietly, in bland conference rooms where hand-picked appointees make decisions that will have far-reaching consequences for our health. Inside one of those nondescript rooms last week, the Advisory Committee on Immunization Practices (ACIP), an independent panel that makes vaccine recommendations to the Centers for Disease Control and Prevention, offered a glimpse of what's to come. The group, few of whom have any expertise in vaccines, infectious diseases or epidemiology, at times cast aside evidence-based science and sowed doubt in some of our most valuable public health tools.

Associated Press
23 minutes ago
- Associated Press
Political Division at Home Fuels Surging Youth Anxiety, According to Data from National Youth Mental Health Tracker
As 60% of Young People Report Worrying About U.S. Politics, Report Reveals that Family Divisions on the Issue are Eroding Youth Mental Health 'The influence isn't coming from social media or elected officials, it's coming from the dinner table.'— Dr. Sema Sgaier, CEO of Surgo Health. WASHINGTON DC, DC, UNITED STATES, June 30, 2025 / / -- A new report from Surgo Health identifies that household political dynamics is a critical and underrecognized driver of emotional strain among young Americans. Drawing on nationally representative data from its Youth Mental Health Tracker—developed in partnership with Pivotal and SHOWTIME/MTV Entertainment Studios—Surgo Health finds that political division within families is increasingly impacting how youth feel, behave, and relate to others. Contrary to prevailing assumptions, the primary vector is not traditional media or social platforms. It's parents and peers. 'The influence isn't coming from social media or elected officials, it's coming from the dinner table,' said Dr. Sema Sgaier, CEO of Surgo Health. 'This data signals a fundamental shift: young people are internalizing political conflict through close relationships, not headlines.' Key Insights 1. Political anxiety is now a baseline reality. 60% of youth report worrying about U.S. politics. Rates spike among girls (71%) and LGBTQ+ youth (79%). Youth who oppose the current administration are 1.8x more likely to report recent mental health challenges. 2. Political division is damaging personal relationships. 1 in 5 youth say political arguments have disrupted family or peer dynamics. Nearly 50% report anxiety when discussing politics in school or at work. 3. Parents and Caregivers are the top political reference point—and emotional proxy. 65% of youth report parents and caregivers as their most cited political source. Youth who feel heard by their caregivers are 1.4x more likely to report a strong sense of meaning in life. Those who feel dismissed are nearly 2x more likely to report hopelessness. Implications for Civic and Mental Health Stakeholders Surgo Health's findings suggest that the nation's polarization is not only eroding political discourse, it's reshaping emotional development and civic readiness. The data points to a new front in youth engagement: addressing the familial environments where civic identity is first formed. 'If we're serious about preparing the next generation for democratic participation, we must also account for the emotional terrain they're navigating today,' Dr. Sgaier added. 'What they're feeling now will define how they show up later.' About Surgo Health Surgo Health is a Public Benefit Corporation pioneering data and analytics to transform how the healthcare system understands people. We uncover the unseen drivers of health—people's beliefs, barriers, and behaviors—and transform that intelligence into scalable products that enable organizations to drive impact, reduce costs, and advance equity. By revealing the human side of healthcare, we're making it more personal, precise, and effective—for everyone. The Youth Mental Health Tracker (YMHT) created by Surgo Health, with support from Pivotal and SHOWTIME/MTVE Entertainment Studios, uncovers the complexities of youth mental health and wellbeing, providing actionable insights that equip communities, policymakers, and healthcare providers to foster environments where young people can truly thrive. About SHOWTIME/MTV Entertainment Studios SHOWTIME/MTV Entertainment Studios produces 120+ series annually, including some of today's biggest hits such as Yellowstone, Emily in Paris, 1923, 1883, George and Tammy, South Park, Tulsa King, The Daily Show, RuPaul's Drag Race, The Challenge and Jersey Shore, to name a few, as well as award-winning documentaries through its acclaimed MTV Documentary Films. MTV Entertainment uses its reach for social impact, spearheading broad change-driven coalitions, content and campaigns on mental health and civic engagement. Karen D Groppe SurgoHealth +1 240-855-8947 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Bloomberg
34 minutes ago
- Bloomberg
Stock Movers: Circle Falls, Disney Climbs, Moderna Meets Flu Shot Goal
On this episode of Stock Movers: Circle Internet (CRCL) falls 2.7% in US premarket trading after JPMorgan — which was a lead in its successful IPO this month — starts coverage with an underweight recommendation, citing a valuation that's beyond the broker's 'comfort zone.' Barclays, meanwhile, gives the stock an overweight rating, saying it's 'one of the only ways' to tap into the stablecoin hype. Disney (DIS) climbs 2% after Jefferies upgraded it's rating to buy, with the broker now seeing limited risk for a slowdown for its key parks division in 2H 2025. Moderna Inc. (MRNA) climbs 5% after saying its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines. The shot's efficacy was 27% higher than a licensed influenza vaccine in adults 50 years and older, the company said in a statement Monday. The trial enrolled more than 40,000 adults across 11 countries. The results set the stage for Moderna to offer a single shot that protects against Covid and flu. US regulators recently told the company that it needed to produce flu vaccine efficacy data — and not just data on the immune response — delaying a potential approval for a combination shot until next year.